Add BrightSurf on Google Email

Estimated long-term benefits of finerenone in heart failure

Long-term treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone is estimated to extend event-free survival by up to 3 years among people with heart failure. The FINEARTS-HF randomized clinical trial found this benefit in patients with mildly reduced or preserved ejection fraction.

SourceJAMA Network·JournalJAMA Cardiology·DateSep 27, 2024

Emerging SARS-CoV-2 resistance after antiviral treatment

Treatment-emergent nirmatrelvir resistance mutations were commonly detected in immunosuppressed individuals, but at low frequencies and transient nature. The study suggests a low risk for the spread of nirmatrelvir resistance in the community with current variants and drug usage patterns.

SourceJAMA Network·JournalJAMA Network Open·DateSep 25, 2024

CRISPR-Cas13: A new frontier in RNA-editing with revolutionary therapeutic potential

The CRISPR-Cas13 system enables temporary gene expression manipulation without permanent genomic changes, holding promise for treating diseases caused by RNA defects. It has been applied to correct mutations linked to Duchenne muscular dystrophy and can be used to alter splicing events, making it a powerful tool in personalized medicine.

SourceNanjing Agricultural University The Academy of Science·JournalBioDesign Research·TypeExperimental study·DateSep 25, 2024

Clinical trial results show low-intensity therapy can achieve positive outcomes for certain pediatric leukemia subtypes

Researchers at St. Jude Children's Research Hospital found that patients with ETV6::RUNX1 and high-hyperdiploid B-ALL can achieve positive outcomes with low-intensity chemotherapy, tailoring treatment based on genetic subtypes and early treatment response. This approach reduces side effects and improves event-free survival rates.

The heart of the question: Who can get Medicare-covered weight loss medicine?

A new study found that up to 10 million people in the US could qualify for Medicare-covered semaglutide injections, depending on their level of cardiovascular risk. Those with higher risk scores would be eligible for full or partial coverage, potentially expanding access to this life-saving medication.

SourceMichigan Medicine - University of Michigan·JournalAnnals of Internal Medicine·TypeData/statistical analysis·DateSep 23, 2024

Study shows psychedelic drug psilocybin gives comparable long-term antidepressant effects to standard antidepressants, but may offer additional benefits

A 6-month study found that psilocybin offered similar improvements to SSRI escitalopram in depressive symptoms, but with greater social functioning and psychological connectedness. Psilocybin may offer an alternative for those not responding to SSRIs, but its benefits are still being studied.

SourceEuropean College of Neuropsychopharmacology·TypeRandomized controlled/clinical trial·DateSep 21, 2024

New drug molecule could lead to new treatments for Parkinson’s disease in younger patients

A novel drug molecule has been found to reactivate a crucial protein called parkin, which plays a key role in maintaining healthy brain cells. The study's findings lay the foundation for the design of personalized treatments for younger patients with specific mutations, offering new hope for a cure for Parkinson's disease.

SourceMcGill University·JournalNature Communications·TypeExperimental study·DateSep 20, 2024

Antidepressant shows promise for treating brain tumors

Researchers at ETH Zurich have found an antidepressant, vortioxetine, effective against glioblastomas, a particularly aggressive brain tumor with no cure. The drug's ability to cross the blood-brain barrier and trigger a signalling cascade makes it promising for treating this deadly tumour.

SourceETH Zurich·JournalNature Medicine·TypeComputational simulation/modeling·DateSep 20, 2024

Using a molecular scissors to improve CAR-T cell therapy

CAR-T cell therapy, a regenerative immunotherapy, has shown promise in treating blood cancers but struggles with T-cell exhaustion. Researchers have discovered that overproduction of the IL-4 protein causes this exhaustion and used CRISPR gene-editing technology to remove it, improving CAR-T cell therapy outcomes.

SourceMayo Clinic·JournalNature Communications·DateSep 12, 2024

UBCO study explores access to psychedelics for therapeutic use

A UBCO study found that patients face barriers when discussing psychedelics with physicians due to stigma and perceived lack of knowledge. The study analyzed data from 800 adults who use psychedelics, revealing that nearly 60% felt less satisfied with communication about psychedelics compared to previous conversations.

SourceUniversity of British Columbia Okanagan campus·JournalPsychedelic Medicine·TypeObservational study·DateSep 10, 2024

FDA issues ‘letter of support’ encouraging use of synuclein-based biomarker, αSyn-SAA, in clinical trials in Parkinson’s and related diseases

The FDA Letter of Support recognizes the potential of αSyn-SAA to accelerate clinical trial design in Parkinson's and related disorders. This biomarker can objectively detect early biology related to these diseases, enabling research toward tailored therapies and potentially delaying or preventing disease onset.

SourceCritical Path Institute (C-Path)·JournalThe Lancet Neurology·DateSep 9, 2024

New study seeks to develop a new treatment strategy to prevent/delay relapse of myeloid leukemia associated with Down syndrome

A four-year grant will help researchers find new clues to the interplay between Down syndrome and myeloid leukemia, focusing on enhancing antileukemic activity of chemotherapy drug cytarabine. The goal is to identify a novel treatment strategy to improve patient outcomes and prevent relapses in ML-DS patients.

New Chinese Medical Journal Pulmonary and Critical Care Medicine study provides key insights into pathogenesis mechanisms of lung fibrosis

A literature review examines key cell-cell interactions driving pulmonary fibrosis, revealing complex interplay between diverse lung cell types and intricate processes. The study highlights potential ligands involved in PF, including tumor necrosis factor, interleukin 1β, and ADAM17, and suggests targeting CCIs for novel therapies.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal - Pulmonary and Critical Care Medicine·TypeLiterature review·DateSep 5, 2024

Promising treatment for incurable prostate cancer

Researchers at Flinders University and University of South Australia have discovered a potential breakthrough in treating the most aggressive forms of prostate cancer using CDKI-73, a novel drug inhibitor. The study found that CDKI-73 effectively blocks the growth of prostate cancer cells while sparing normal cells.

SourceFlinders University·JournalBritish Journal of Cancer·TypeRandomized controlled/clinical trial·DateSep 1, 2024

Study combines data, molecular simulations to accelerate drug discovery

Researchers have developed a new method to increase speed and success rates in drug discovery by combining data from the Library of Integrated Network-based Cellular Signatures with targeted docking simulations. This approach can accelerate the drug research process, identifying potentially effective compounds more efficiently.

SourceUniversity of Cincinnati·JournalScience Advances·TypeComputational simulation/modeling·DateAug 30, 2024

Gene therapy gets a turbo boost from University of Hawaii researchers

Researchers at the University of Hawaii have developed a new gene editing technology that can efficiently deliver healthy genes to the body. This method addresses limitations of current methods and has shown success rates of up to 96%, potentially leading to faster and more affordable treatments for various genetic diseases.

SourceUniversity of Hawaii at Manoa·JournalNucleic Acids Research·TypeExperimental study·DateAug 29, 2024

UVA research cracks the autism code, making the neurodivergent brain visible

A multi-university research team led by University of Virginia engineering professor Gustavo K. Rohde has developed a system that can accurately spot genetic markers of autism in brain images. The system uses generative computer modeling technique called transport-based morphometry, which reveals brain structure patterns that predict v...

UVA engineers design lookalike drug carrier to evade lung’s lines of defense

Researchers at the University of Virginia School of Engineering and Applied Science have designed a drug-carrying molecule that can slip past the lung's natural defenses. The nanocarrier, called PEG-BB, is shaped like a bottlebrush and mimics the properties of mucus, allowing it to move quickly through the airway.

Precision therapy for metastatic prostate cancer improves survival

A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.

SourceKarolinska Institutet·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateAug 20, 2024

Korea University offers new breakthrough for Hepatitis C to improve life expectancy

A new study by Korea University College of Medicine shows that direct-acting antivirals significantly reduce liver-related clinical outcomes and lower the risk of disease progression to cancer or cirrhosis, increasing life expectancy for patients with Hepatitis C. The treatment approach has a high effectiveness rate of 90%.

SourceKorea University College of Medicine·JournalEClinicalMedicine·TypeData/statistical analysis·DateAug 20, 2024

Preliminary study shows potential of Manuka honey as a nutraceutical for breast cancer

A new study by UCLA investigators found that Manuka honey contains compounds that can help reduce tumor growth in preclinical models. The research suggests that Manuka honey could potentially be developed into a natural supplement or standalone treatment for ER-positive breast cancer, which accounts for most breast cancer cases.

A wearable sensor supported by machine learning models is used to monitor and quantify freezing of gait (FOG) episodes in people with Parkinson's disease

A wearable sensor supported by machine learning models can continuously monitor and quantify FOG episodes, providing an accurate picture of a patient's condition. This technology has the potential to support the development of new treatments and improve the lives of people with Parkinson's disease.

SourceTel-Aviv University·JournalNature Communications·DateAug 18, 2024